The use of DDAVP in children with bleeding disorders

Pediatric Blood and Cancer

Volumn 60, Issue SUPPL.1, 2013, Pages

  Ben Ami, Tal ^a   Revel Vilk, Shoshana ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

DDAVP; Desmopressin; Hemophilia A; Platelet function disorder; Von Willebrand disease

Indexed keywords

BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; RISTOCETIN; VASOPRESSIN V2 RECEPTOR; VON WILLEBRAND FACTOR;

BLEEDING TENDENCY; BLEEDING TIME; BLOOD CLOTTING FACTOR 11 DEFICIENCY; CHILDHOOD DISEASE; DISEASE CLASSIFICATION; EHLERS DANLOS SYNDROME; GAUCHER DISEASE; GENE MUTATION; GENETIC DISORDER; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MARFAN SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REPEATED DRUG DOSE; REVIEW; THROMBOCYTE DYSFUNCTION; VON WILLEBRAND DISEASE;

BLOOD COAGULATION DISORDERS, INHERITED; BLOOD PLATELETS; CHILD; CHILD, PRESCHOOL; DEAMINO ARGININE VASOPRESSIN; HEMOPHILIA A; HEMOSTASIS; HUMANS; PLATELET FUNCTION TESTS; VON WILLEBRAND DISEASES;

EID: 84869223744     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24335     Document Type: Review

References (35)

1. Mannucci PM. Desmopressin (DDAVP) in the treatment of bleeding disorders: The first twenty years. Haemophilia 2000; 6: 60-67.
2. Sloand EM, Alyono D, Klein HG, et al. 1-Deamino-8-D-arginine vasopressin (DDAVP) increases platelet membrane expression of glycoprotein Ib in patients with disorders of platelet function and after cardiopulmonary bypass. Am J Hematol 1994; 46: 199-207.
3. Mannucci PM, Ruggeri ZM, Pareti FI, et al. 1-Deamino-8-D-arginine vasopressin: A new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977; 1: 869-872.
4. Sutor AH. Desmopressin (DDAVP) in bleeding disorders of childhood. Semin Thromb Hemost 1998; 24: 555-566.
5. Thumfart J, Roehr CC, Kapelari K, et al. Desmopressin associated symptomatic hyponatremic hypervolemia in children. Are there predictive factors? J Urol 2005; 174: 294-298, discussion 298.
6. Kaufmann JE, Vischer UM. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP). J Thromb Haemost 2003; 1: 682-689.
7. Cattaneo M, Federici AB, Lecchi A, et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb Haemost 1999; 82: 35-39.
8. Federici AB. The use of desmopressin in von Willebrand disease: The experience of the first 30 years (1977-2007). Haemophilia 2008; 14: 5-14.
9. Rodeghiero F, Castaman G, Di Bona E, et al. Consistency of responses to repeated DDAVP infusions in patients with von Willebrand's disease and hemophilia A. Blood 1989; 74: 1997-2000.
10. Revel-Vilk S, Schmugge M, Carcao MD, et al. Desmopressin (DDAVP) responsiveness in children with von Willebrand disease. J Pediatr Hematol Oncol 2003; 25: 874-879.
11. Mannucci PM. How I treat patients with von Willebrand disease. Blood 2001; 97: 1915-1919.
12. Nolan B, White B, Smith J, et al. Desmopressin: Therapeutic limitations in children and adults with inherited coagulation disorders. Br J Haematol 2000; 109: 865-869.
13. Sanchez-Luceros A, Meschengieser SS, Woods AI, et al. Biological and clinical response to desmopressin (DDAVP) in a retrospective cohort study of children with low von Willebrand factor levels and bleeding history. Thromb Haemost 2010; 104: 984-989.
14. Seary ME, Feldman D, Carcao MD. DDAVP responsiveness in children with mild or moderate haemophilia A correlates with age, endogenous FVIII:C level and with haemophilic genotype. Haemophilia 2012; 18: 50-55.
15. Revel-Vilk S, Blanchette VS, Sparling C, et al. DDAVP challenge tests in boys with mild/moderate haemophilia A. Br J Haematol 2002; 117: 947-951.
16. Werner EJ, Broxson EH, Tucker EL, et al. Prevalence of von Willebrand disease in children: A multiethnic study. J Pediatr 1993; 123: 893-898.
17. Mannucci PM, Franchini M, Castaman G, et al. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009; 7: 117-126.
18. Castaman G, Lethagen S, Federici AB, et al. Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): Results from the European Study MCMDM-1VWD. Blood 2008; 111: 3531-3539.
19. Schneppenheim R, Budde U, Beutel K, et al. Response to DDAVP in children with von Willebrand disease type 2. Hamostaseologie 2009; 29: 143-148.
20. Hanebutt FL, Rolf N, Loesel A, et al. Evaluation of desmopressin effects on haemostasis in children with congenital bleeding disorders. Haemophilia 2008; 14: 524-530.
21. Israels SJ, Kahr WH, Blanchette VS, et al. Platelet disorders in children: A diagnostic approach. Pediatr Blood Cancer 2011; 56: 975-983.
22. Coppola A, Di Minno G. Desmopressin in inherited disorders of platelet function. Haemophilia 2008; 14: 31-39.
23. Franchini M, Manzato F, Salvagno GL, et al. The use of desmopressin in congenital factor XI deficiency: A systematic review. Ann Hematol 2009; 88: 931-935.
24. Ehl S, Severin T, Sutor AH. DDAVP (desmopressin; 1-deamino-cys-8-D-arginine-vasopressin) treatment in children with haemophilia B. Br J Haematol 2000; 111: 1260-1262.
25. Guglielmone H, Minoldo S, Jarchum G. Response to the DDAVP test in a patient with combined deficiency of factor V and factor VIII. Haemophilia 2009; 15: 838-839.
26. Devecioglu O, Eryilmaz E, Celik D, et al. Circumcision in a combined factor V and factor VIII deficiency using desmopressin (DDAVP). Turk J Pediatr 2002; 44: 146-147.
27. Mast KJ, Nunes ME, Ruymann FB, et al. Desmopressin responsiveness in children with Ehlers-Danlos syndrome associated bleeding symptoms. Br J Haematol 2009; 144: 230-233.
28. Franchini M, Lippi G, Veneri D. Efficacy of desmopressin in preventing hemorrhagic complications in a patient with Marfan syndrome undergoing cardiac surgery. Blood Coagul Fibrinolysis 2006; 17: 325-326.
29. Parker RI, Grewal RP, McKeown LP, et al. Effect of platelet count on the DDAVP-induced shortening of the bleeding time in thrombocytopenic Gaucher's patients. Am J Pediatr Hematol Oncol 1992; 14: 39-43.
30. Crescenzi G, Landoni G, Biondi-Zoccai G, et al. Desmopressin reduces transfusion needs after surgery: A meta-analysis of randomized clinical trials. Anesthesiology 2008; 109: 1063-1076.
31. Gurusamy KS, Li J, Sharma D, et al. Pharmacological interventions to decrease blood loss and blood transfusion requirements for liver resection. Cochrane Database Syst Rev 2009; CD008085.
32. Akin M, Karapinar DY, Balkan C, et al. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children. Clin Appl Thromb Hemost 2011; 17: 441-448.
33. Santiago-Borrero PJ, Casanova R. Response of patients with hemophilia A and von Willebrand disease to desmopressin (DDAVP). Bol Asoc Med P R 1990; 82: 207-210.
34. DiMichele DM, Hathaway WE. Use of DDAVP in inherited and acquired platelet dysfunction. Am J Hematol 1990; 33: 39-45.
35. Cordova A, Barrios NJ, Ortiz I, et al. Poor response to desmopressin acetate (DDAVP) in children with Hermansky-Pudlak syndrome. Pediatr Blood Cancer 2005; 44: 51-54.